tralokinumab: clinical use

Prescribing considerations

• Initiation should be supervised by clinicians experienced in diagnosing and treating atopic dermatitis.
• May be used with or without topical corticosteroids; topical calcineurin inhibitors may be reserved for appropriate problem areas.
• Treat pre-existing helminth infection before initiation. If infection develops and does not respond to treatment, interrupt tralokinumab until it resolves.
• Bring live and live-attenuated immunisations up to date before treatment where appropriate.
• Record the product name and batch number to support biologic traceability.
• Arrange ophthalmological assessment when conjunctivitis does not resolve with standard management.

Contraindications and cautions

• Hypersensitivity to tralokinumab or any excipient, including possible reactions to polysorbate 80.

Monitoring

• Assess control of atopic dermatitis and ongoing treatment benefit.
• Monitor for hypersensitivity, persistent conjunctivitis, eye pain or visual change, and symptoms suggesting helminth infection.
• No routine laboratory-monitoring programme is specified in the selected product information.

Clinical pharmacology

A fully human IgG4 monoclonal antibody that neutralises interleukin-13 by blocking interaction with the IL-13 receptor complex. It is degraded through proteolytic pathways rather than hepatic enzyme metabolism or renal elimination; its reported half-life is approximately 22 days.

Formulation and product differences

• The selected product is a single-use pre-filled pen for subcutaneous injection.
• The solution should be clear to opalescent and colourless to pale yellow.
• It contains polysorbate 80 and is essentially sodium-free.
• Pens require refrigerated, light-protected storage and must not be frozen. Limited room-temperature storage is permitted under the conditions in the product information.

Injection

Route: Parenteral

Strengths: 150 mg, 300 mg